clonidine has been researched along with Dystonia in 11 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Dystonia: An attitude or posture due to the co-contraction of agonists and antagonist muscles in one region of the body. It most often affects the large axial muscles of the trunk and limb girdles. Conditions which feature persistent or recurrent episodes of dystonia as a primary manifestation of disease are referred to as DYSTONIC DISORDERS. (Adams et al., Principles of Neurology, 6th ed, p77)
| Excerpt | Relevance | Reference |
|---|---|---|
| "An 11-year-old male receiving aripiprazole, methylphenidate, and clonidine developed acute masseter dystonia inhibiting tracheal intubation after induction of general anesthesia with propofol and rocuronium." | 7.85 | Acute masseter dystonia in a pediatric patient receiving aripiprazole and methylphenidate following induction of general anesthesia. ( Duncan-Wiebe, G; LeRiger, M; Shukry, M; Williams, J, 2017) |
| "High dose clonidine administered via different routes can be used in the acute management of severe exacerbations of dystonia." | 7.85 | Safety and efficacy of high-dose enteral, intravenous, and transdermal clonidine for the acute management of severe intractable childhood dystonia and status dystonicus: An illustrative case-series. ( Arichi, T; Kaminska, M; Lin, JP; Lumsden, DE; Nakou, V; Tomlin, S; Williamson, K, 2017) |
| "An 11-year-old male receiving aripiprazole, methylphenidate, and clonidine developed acute masseter dystonia inhibiting tracheal intubation after induction of general anesthesia with propofol and rocuronium." | 3.85 | Acute masseter dystonia in a pediatric patient receiving aripiprazole and methylphenidate following induction of general anesthesia. ( Duncan-Wiebe, G; LeRiger, M; Shukry, M; Williams, J, 2017) |
| " The aims of this study were therefore (1) to investigate the anti-dyskinetic effects of piribedil on L-DOPA-induced contralateral turning behaviour, locomotive dyskinesias (LD), axial dystonia (AD), orolingual dyskinesia (OD) and forelimb dyskinesia (FD) and (2) to compare these effects to the α(2) adrenoceptor antagonist, idazoxan, or the α(2) adrenoceptor agonist, clonidine." | 3.79 | The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms. ( Gerlach, M; Halley, P; Riederer, P; van den Buuse, M, 2013) |
| "Twenty-nine patients with tardive dyskinesia (n = 20) or related syndromes [spontaneous dyskinesia (n = 3), levodopa-induced dyskinesia (n = 3), tardive dystonia (n = 3)] were treated with clonidine." | 3.67 | Clonidine therapy for tardive dyskinesia and related syndromes. ( Koga, I; Nishikawa, T; Tanaka, M; Tsuda, A; Uchida, Y, 1984) |
| "Among the more common symptoms is spasticity." | 2.41 | Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. ( Schapiro, RT, 2001) |
| "Movement disorders are subdivided based on a variety of criteria." | 2.38 | Treatment of hyperkinetic movement disorders. ( Bressman, SB; Greene, PE, 1990) |
| "Isolated dystonia or spasticity was infrequently seen, with a mixed picture of dystonia and spasticity ± choreoathetosis identified in 194/275 (70." | 1.51 | Pharmacological management of abnormal tone and movement in cerebral palsy. ( Amin, S; Basu, A; Cadwgan, J; Crowe, B; DeAlwis, Y; Devlin, A; Kumar, R; Lodh, R; Lumsden, DE; Lundy, CT; Mordekar, SR; Smith, M, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (9.09) | 18.7374 |
| 1990's | 2 (18.18) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Bohn, E | 1 |
| Goren, K | 1 |
| Switzer, L | 1 |
| Falck-Ytter, Y | 1 |
| Fehlings, D | 1 |
| LeRiger, M | 1 |
| Williams, J | 1 |
| Duncan-Wiebe, G | 1 |
| Shukry, M | 1 |
| Nakou, V | 1 |
| Williamson, K | 1 |
| Arichi, T | 1 |
| Lumsden, DE | 2 |
| Tomlin, S | 1 |
| Kaminska, M | 1 |
| Lin, JP | 1 |
| Crowe, B | 1 |
| Basu, A | 1 |
| Amin, S | 1 |
| Devlin, A | 1 |
| DeAlwis, Y | 1 |
| Kumar, R | 1 |
| Lodh, R | 1 |
| Lundy, CT | 1 |
| Mordekar, SR | 1 |
| Smith, M | 1 |
| Cadwgan, J | 1 |
| McCluggage, HL | 1 |
| Gerlach, M | 1 |
| Halley, P | 1 |
| Riederer, P | 1 |
| van den Buuse, M | 1 |
| Kasim, S | 1 |
| Jinnah, HA | 1 |
| Nishikawa, T | 1 |
| Tanaka, M | 1 |
| Tsuda, A | 1 |
| Koga, I | 1 |
| Uchida, Y | 1 |
| Schapiro, RT | 1 |
| Lang, AE | 1 |
| Riley, DE | 1 |
| Bressman, SB | 1 |
| Greene, PE | 1 |
3 reviews available for clonidine and Dystonia
| Article | Year |
|---|---|
Pharmacological and neurosurgical interventions for individuals with cerebral palsy and dystonia: a systematic review update and meta-analysis.
Topics: Baclofen; Botulinum Toxins; Cerebral Palsy; Clonidine; Deep Brain Stimulation; Dystonia; Humans; Inj | 2021 |
Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.
Topics: Acetates; Amines; Autoimmune Diseases; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Cannabin | 2001 |
Treatment of hyperkinetic movement disorders.
Topics: Benzodiazepines; Clonidine; Dystonia; Humans; Levodopa; Movement Disorders | 1990 |
1 trial available for clonidine and Dystonia
| Article | Year |
|---|---|
Tizanidine in cranial dystonia.
Topics: Brain Stem; Clonidine; Dystonia; Female; Humans; Male; Meige Syndrome; Middle Aged; Muscle Relaxants | 1992 |
7 other studies available for clonidine and Dystonia
| Article | Year |
|---|---|
Acute masseter dystonia in a pediatric patient receiving aripiprazole and methylphenidate following induction of general anesthesia.
Topics: Anesthesia, General; Antipsychotic Agents; Appendectomy; Aripiprazole; Central Nervous System Stimul | 2017 |
Safety and efficacy of high-dose enteral, intravenous, and transdermal clonidine for the acute management of severe intractable childhood dystonia and status dystonicus: An illustrative case-series.
Topics: Administration, Cutaneous; Administration, Intravenous; Administration, Oral; Adolescent; Adrenergic | 2017 |
Pharmacological management of abnormal tone and movement in cerebral palsy.
Topics: Adolescent; Baclofen; Botulinum Toxins; Cerebral Palsy; Child; Child Health Services; Child, Prescho | 2019 |
Changing from continuous SC to transdermal clonidine to treat dystonia in a teenage boy with end-stage leucodystrophy.
Topics: Administration, Cutaneous; Adolescent; Analgesics; Clonidine; Dystonia; Fatal Outcome; Humans; Male; | 2018 |
The effect of piribedil on L-DOPA-induced dyskinesias in a rat model of Parkinson's disease: differential role of α(2) adrenergic mechanisms.
Topics: Adrenergic Agents; Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; An | 2013 |
Pharmacologic thresholds for self-injurious behavior in a genetic mouse model of Lesch-Nyhan disease.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2002 |
Clonidine therapy for tardive dyskinesia and related syndromes.
Topics: Adult; Aged; Clonidine; Dyskinesia, Drug-Induced; Dystonia; Female; Humans; Levodopa; Male; Middle A | 1984 |